Use of IgM monoclonal reagents licensed for tube tests in column agglutination technology

F. Morelati, A. Burlini, K. J. Reis, F. Drago, N. Revelli, M. A. Villa, A. Guffanti, Z. Italiano, A. Parravicini, P. Rebulla, G. Sirchia

Research output: Contribution to journalArticlepeer-review


BACKGROUND: Red cell (RBC) phenotyping using column agglutination technology (CAT) is currently limited by the reagents formulated in the system. To overcome this limitation, it was investigated whether monoclonal IgM reagents licensed for use with tub tests produced valid results with CAT. STUDY DESIGN AND METHODS: Commercial CAT, does not contain antisera, was used to evaluate Procedures A (40 μL of reagent and 10 μL of 4% RBCs) and B (50 μL of reagent and 50 μL of 0.8% RBCs) with or without incubation at room temperature. In Study 1, reagents were tested to determine whether potentiators inhibit the passage of antigen-negative RBCs through the column. In Study 2, CAT sensitivity was measured by the use of potency titrations to define a procedure for each reagent that matched or exceeded that of the tube method. In Study 3, the specificity of each reagent was determined in parallel with the CAT and tube tests. Typing of 1644 samples was performed. RESULTS: Study 1: Free passage was obtained with all reagents. Study 2: Immediate-spin methods using CAT produced the same results as the tube method. Study 3: With 8048 comparisons made, discrepant results were found in 32 transfused patients and in 6 cord blood samples, mainly with Lewis reagents. With comparison of CAT and the standard tube method, complete agreement was obtained with Kell reagents, 99.9-percent agreement with Kidd reagents, and 98.9-percent and 99.4-percent agreement with Lewis reagents. CONCLUSION: Most examined reagents seen suitable for use with CAT.

Original languageEnglish
Pages (from-to)1037-1040
Number of pages4
Issue number11-12
Publication statusPublished - Nov 1998

ASJC Scopus subject areas

  • Hematology
  • Immunology


Dive into the research topics of 'Use of IgM monoclonal reagents licensed for tube tests in column agglutination technology'. Together they form a unique fingerprint.

Cite this